Compare COHU & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COHU | PGEN |
|---|---|---|
| Founded | 1947 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.6B |
| IPO Year | 1994 | 2013 |
| Metric | COHU | PGEN |
|---|---|---|
| Price | $47.68 | $5.54 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $40.50 | $8.33 |
| AVG Volume (30 Days) | 1.0M | ★ 4.0M |
| Earning Date | 04-30-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $452,956,000.00 | $230,981,000.00 |
| Revenue This Year | $14.38 | $1,115.92 |
| Revenue Next Year | $19.12 | $81.04 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 12.74 | N/A |
| 52 Week Low | $17.80 | $1.57 |
| 52 Week High | $74.60 | $6.04 |
| Indicator | COHU | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 38.08 | 58.35 |
| Support Level | $43.64 | $3.96 |
| Resistance Level | $52.43 | $6.04 |
| Average True Range (ATR) | 3.54 | 0.28 |
| MACD | -0.88 | -0.01 |
| Stochastic Oscillator | 6.42 | 82.95 |
Cohu Inc is a supplier of semiconductor test and inspection handlers, micro-electro-mechanical system (MEMS) test modules, test contactors, and thermal sub-systems used by semiconductor manufacturers and test subcontractors. The company's products include Semiconductor ATE (Automated Test Equipment), Semiconductor Handlers, Interface Products such as test contactors, probe heads, and probe pins, Spares and Kits, Bare Board PCB Test Systems, and services. It has one reportable segment, Semiconductor Test and Inspection Equipment (Semiconductor Test & Inspection). Geographically, the company generates maximum revenue from the Philippines, followed by Taiwan, China, Malaysia, the United States, Singapore, and the Rest of the world.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.